MEDNAX, Inc. is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company's national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. As of December 31, 2016, the Company had over 1,390 affiliated physicians providing anesthesia care to patients in connection with surgical and other procedures, as well as pain management. As of December 31, 2016, the Company had 270 affiliated physicians providing maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Healthcare Facilities & Services
- Sub-Industry: Health Care Services
- Symbol: NYSE:MD
- CUSIP: 58502B10
- Web: www.mednax.com
Capitalization:- Market Cap: $3.943 billion
- Outstanding Shares: 93,569,000
Average Prices:- 50 Day Moving Avg: $43.21
- 200 Day Moving Avg: $56.37
- 52 Week Range: $40.78 - $72.13
P/E:- Trailing P/E Ratio: 13.42
- Foreward P/E Ratio: 12.65
- P/E Growth: 0.88
Sales & Book Value:- Annual Revenue: $3.34 billion
- Price / Sales: 1.18
- Book Value: $30.79 per share
- Price / Book: 1.37
Profitability:- EBIDTA: $628.4 million
- Net Margins: 8.78%
- Return on Equity: 11.89%
- Return on Assets: 6.10%
Debt:- Debt-to-Equity Ratio: 0.62%
- Current Ratio: 1.59%
- Quick Ratio: 1.59%
Misc:- Average Volume: 1.04 million shs.
- Beta: 0.4
- Short Ratio: 8.38
Frequently Asked Questions for Mednax (NYSE:MD)
What is Mednax's stock symbol?
Mednax trades on the New York Stock Exchange (NYSE) under the ticker symbol "MD."
How were Mednax's earnings last quarter?
Mednax, Inc (NYSE:MD) issued its quarterly earnings results on Friday, July, 28th. The company reported $0.85 earnings per share for the quarter, topping analysts' consensus estimates of $0.81 by $0.04. The company had revenue of $843 million for the quarter, compared to analyst estimates of $849.49 million. Mednax had a return on equity of 11.89% and a net margin of 8.78%. The business's revenue for the quarter was up 9.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.03 EPS. View Mednax's Earnings History.
When will Mednax make its next earnings announcement?
What guidance has Mednax issued on next quarter's earnings?
Mednax issued an update on its third quarter earnings guidance on Friday, July, 28th. The company provided EPS guidance of $0.83-0.88 for the period, compared to the Thomson Reuters consensus estimate of $0.98.
Where is Mednax's stock going? Where will Mednax's stock price be in 2017?
10 equities research analysts have issued 1 year price targets for Mednax's stock. Their forecasts range from $46.00 to $69.00. On average, they anticipate Mednax's share price to reach $56.63 in the next twelve months. View Analyst Ratings for Mednax.
What are analysts saying about Mednax stock?
Here are some recent quotes from research analysts about Mednax stock:
- 1. According to Zacks Investment Research, "Mednax, Inc., formerly Pediatrix Medical Group, Inc. is a healthcare services company that focuses on physician services for newborn, maternal-fetal, pediatric subspecialty and anesthesia care. The company ,through its subsidiaries, provides these services in the United States and Puerto Rico. In addition, MEDNAX engages in clinical research, monitoring clinical outcomes, and implementing clinical initiatives. " (4/27/2017)
- 2. Jefferies Group LLC analysts commented, "Following MD's 5% EPS miss in Q4, we believe our Hold thesis from our December downgrade still holds and would expect the stock to give up some of its premium valuation pending improved earnings visibility. Broader birth trends remain subdued, MD faces its toughest comp of the year in Q1-17, and the company's deal flow remains relatively moderate, leading us to believe that the achievability of Q1 guidance (following 3 consecutive EPS misses) remains uncertain." (2/8/2017)
Who are some of Mednax's key competitors?
Some companies that are related to Mednax include NMC Health PLC (NMC), HealthSouth Corporation (HLS), Acadia Healthcare Company (ACHC), Molina Healthcare (MOH), Chemed Corp. (CHE), Select Medical Holdings Corporation (SEM), LifePoint Health (LPNT), Udg Healthcare PLC (UDG), Tenet Healthcare Corporation (THC), HMS Holdings Corp (HMSY), Community Health Systems (CYH), China Cord Blood Corporation (CO), HealthStream (HSTM), Kindred Healthcare (KND), American Renal Associates Holdings (ARA), Georgia Healthcare Group PLC (GHG), Cambian Group PLC (CMBN) and Concord Medical Services Holdings Limited (CCM).
Who are Mednax's key executives?
Mednax's management team includes the folowing people:
- Cesar L. Alvarez, Chairman of the Board
- Joseph M. Calabro, President, Chief Operating Officer
- Roger J. Medel M.D., Chief Executive Officer, Director
- Vivian Lopez-Blanco, Chief Financial Officer, Treasurer
- David A. Clark, President - MEDNAX National Medical Group Division
- John C. Pepia, Senior Vice President, Chief Accounting Officer
- Dominic J. Andreano, Senior Vice President, General Counsel, Secretary
- Manuel Kadre, Lead Independent Director
- Karey D. Barker, Independent Director
- Waldemar A. Carlo M.D., Independent Director
Who owns Mednax stock?
Mednax's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.83%), Vanguard Group Inc. (8.07%), Longview Partners Guernsey LTD (5.40%), FMR LLC (3.27%), State Street Corp (3.15%) and Victory Capital Management Inc. (2.59%). Company insiders that own Mednax stock include Dominic J Andreano, Enrique Sosa, John C Pepia, Joseph M Calabro, Karl B Wagner, Manuel Kadre, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Michael D Stanley, Paul G Gabos and Vivian Lopez-Blanco. View Institutional Ownership Trends for Mednax.
Who sold Mednax stock? Who is selling Mednax stock?
Mednax's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, William Blair Investment Management LLC, Eagle Asset Management Inc., Wasatch Advisors Inc., Mawer Investment Management Ltd., Janus Henderson Group PLC, Nordea Investment Management AB and BB&T Securities LLC. Company insiders that have sold Mednax stock in the last year include Dominic J Andreano, Enrique Sosa, John C Pepia, Joseph M Calabro, Md Carlo A Waldemar, Md Pascal J Goldschmidt, Paul G Gabos and Vivian Lopez-Blanco. View Insider Buying and Selling for Mednax.
Who bought Mednax stock? Who is buying Mednax stock?
Mednax's stock was purchased by a variety of institutional investors in the last quarter, including Thompson Siegel & Walmsley LLC, Balyasny Asset Management LLC, HealthCor Management L.P., Fiduciary Management Inc. WI, Longview Partners Guernsey LTD, Victory Capital Management Inc., Lord Abbett & CO. LLC and Wedge Capital Management L L P NC. Company insiders that have bought Mednax stock in the last two years include Manuel Kadre and Md Pascal J Goldschmidt. View Insider Buying and Selling for Mednax.
How do I buy Mednax stock?
Shares of Mednax can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mednax's stock price today?
One share of Mednax stock can currently be purchased for approximately $42.14.
MarketBeat Community Rating for Mednax (NYSE MD)MarketBeat's community ratings are surveys of what our community members think about Mednax and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Mednax (NYSE:MD) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 7 Hold Ratings, 2 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.10) |
| Consensus Price Target: | $56.63 (34.37% upside) |
Analysts' Ratings History for Mednax (NYSE:MD)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/17/2017 | KeyCorp | Upgrade | Sector Weight -> Overweight | $51.00 | Low |  |
| 9/3/2017 | Robert W. Baird | Reiterated Rating | Hold | $47.00 | Medium | |
| 8/1/2017 | Mizuho | Reiterated Rating | Neutral | $62.00 -> $48.00 | Medium | |
| 7/30/2017 | Jefferies Group LLC | Set Price Target | Hold | $53.00 -> $46.00 | Medium | |
| 6/22/2017 | Stephens | Upgrade | Equal Weight -> Overweight | $55.00 -> $68.00 | High | |
| 5/25/2017 | Stifel Nicolaus | Lower Price Target | Hold | $65.00 -> $58.00 | Low | |
| 5/4/2017 | Bank of America Corporation | Downgrade | Buy -> Underperform | | Low | |
| 3/10/2017 | J P Morgan Chase & Co | Reiterated Rating | Overweight -> Neutral | $69.00 | Low | |
| 12/9/2016 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Neutral | $66.00 | N/A | |
| 10/27/2016 | Raymond James Financial, Inc. | Downgrade | Outperform -> Market Perform | | N/A | |
| 8/17/2016 | Citigroup Inc. | Lower Price Target | Neutral | $76.00 -> $72.00 | N/A | |
| 3/14/2016 | Piper Jaffray Companies | Reiterated Rating | Overweight | $76.00 | N/A | |
| 3/7/2016 | Susquehanna Bancshares Inc | Downgrade | Positive -> Neutral | $94.00 -> $70.00 | N/A | |
(Data available from 9/25/2015 forward)
Earnings History for Mednax (NYSE:MD)Earnings History by Quarter for Mednax (NYSE MD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/25/2017 | | $0.87 | | | | | N/A | |
| 7/28/2017 | Q2 2017 | $0.81 | $0.85 | $849.49 million | $843.00 million | View | N/A | |
| 5/4/2017 | Q1 2017 | $0.74 | $0.75 | $837.01 million | $835.60 million | View | N/A | |
| 2/7/2017 | Q416 | $1.06 | $1.00 | $842.15 million | $831.00 million | View | Listen | |
| 10/27/2016 | Q316 | $1.05 | $1.09 | $821.18 million | $828.00 million | View | Listen | |
| 7/28/2016 | Q216 | $1.07 | $1.03 | $775.68 million | $772.00 million | View | Listen | |
| 4/28/2016 | Q116 | $0.86 | $0.87 | $741.49 million | $752.60 million | View | Listen | |
| 2/4/2016 | Q415 | $1.10 | $1.13 | $748.02 million | $742.00 million | View | Listen | |
| 10/29/2015 | Q315 | $0.97 | $1.10 | $730.63 million | $722.30 million | View | Listen | |
| 7/30/2015 | Q215 | $0.88 | $0.97 | $677.02 million | $676.60 million | View | Listen | |
| 4/30/2015 | Q115 | $0.71 | $0.72 | $641.24 million | $639.40 million | View | Listen | |
| 1/29/2015 | Q414 | $0.87 | $0.89 | $637.90 million | $651.00 million | View | Listen | |
| 10/30/2014 | Q314 | $0.85 | $0.86 | $619.61 million | $627.00 million | View | Listen | |
| 7/31/2014 | Q214 | $0.78 | $0.79 | $603.00 million | $595.54 million | View | Listen | |
| 5/1/2014 | Q114 | $0.63 | $0.63 | $574.80 million | $566.00 million | View | Listen | |
| 1/30/2014 | Q4 | $0.75 | $0.20 | $555.30 million | $567.00 million | View | Listen | |
| 10/31/2013 | Q313 | $1.48 | $1.52 | $556.63 million | $555.00 million | View | Listen | |
| 7/30/2013 | Q2 2013 | $1.36 | $1.37 | $533.39 million | $529.18 million | View | Listen | |
| 5/2/2013 | Q1 2013 | $1.09 | $1.10 | $504.24 million | $502.70 million | View | Listen | |
| 1/31/2013 | Q4 2012 | $1.30 | $1.32 | $473.70 million | $471.30 million | View | Listen | |
| 11/1/2012 | Q312 | $1.28 | $1.32 | $470.60 million | $473.10 million | View | N/A | |
| 7/31/2012 | | $1.19 | $1.22 | | | View | N/A | |
| 5/3/2012 | | $1.00 | $0.98 | | | View | N/A | |
| 2/2/2012 | | $1.19 | $1.19 | | | View | N/A | |
| 11/1/2011 | | $1.18 | $1.19 | | | View | N/A | |
| 8/2/2011 | | $1.15 | $1.15 | | | View | N/A | |
| 5/3/2011 | | $0.91 | $0.94 | | | View | N/A | |
| 2/3/2011 | | $1.12 | $1.12 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Mednax (NYSE:MD)2017 EPS Consensus Estimate: $3.66
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $0.80 | $0.81 | $0.81 |
| Q2 2017 | 2 | $0.99 | $1.00 | $1.00 |
| Q3 2017 | 3 | $0.77 | $1.07 | $0.91 |
| Q4 2017 | 3 | $0.79 | $1.09 | $0.94 |
(Data provided by Zacks Investment Research)
Dividend History for Mednax (NYSE:MD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Mednax (NYSE:MD)Insider Ownership Percentage: 2.40%
Insider Trades by Quarter for Mednax (NYSE:MD)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/12/2017 | John C Pepia | Insider | Sell | 3,000 | $42.85 | $128,550.00 | |
| 6/14/2017 | Md Pascal J Goldschmidt | Director | Sell | 1,969 | $57.57 | $113,355.33 | |
| 6/1/2017 | Joseph M Calabro | Insider | Sell | 23,327 | $55.00 | $1,282,985.00 | |
| 5/5/2017 | Manuel Kadre | Director | Buy | 21,704 | $55.79 | $1,210,866.16 | |
| 5/5/2017 | Vivian Lopez-Blanco | CFO | Sell | 7,778 | $55.82 | $434,167.96 | |
| 2/23/2017 | Enrique Sosa | Director | Sell | 10,668 | $69.65 | $743,026.20 | |
| 2/17/2017 | Vivian Lopez-Blanco | CFO | Sell | 15,164 | $70.01 | $1,061,631.64 | |
| 2/16/2017 | Dominic J Andreano | SVP | Sell | 6,000 | $69.59 | $417,540.00 | |
| 2/16/2017 | John C Pepia | Insider | Sell | 2,500 | $69.58 | $173,950.00 | |
| 2/16/2017 | Paul G Gabos | Director | Sell | 21,336 | $69.63 | $1,485,625.68 | |
| 2/10/2017 | Md Pascal J Goldschmidt | Director | Sell | 25,294 | $67.82 | $1,715,439.08 | |
| 2/9/2017 | Md Carlo A Waldemar | Director | Sell | 5,334 | $67.90 | $362,178.60 | |
| 1/17/2017 | Vivian Lopez-Blanco | CFO | Sell | 10,000 | $70.95 | $709,500.00 | |
| 12/7/2016 | Md Pascal J Goldschmidt | Director | Buy | 2,100 | $66.52 | $139,692.00 | |
| 9/14/2016 | Md Pascal J Goldschmidt | Director | Sell | 1,500 | $65.01 | $97,515.00 | |
| 6/13/2016 | Dominic J Andreano | SVP | Sell | 3,922 | $68.80 | $269,833.60 | |
| 6/8/2016 | Md Carlo A Waldemar | Director | Sell | 5,334 | $70.50 | $376,047.00 | |
| 6/7/2016 | Karl B Wagner | Insider | Sell | 27,482 | $68.45 | $1,881,142.90 | |
| 6/1/2016 | Joseph M Calabro | COO | Sell | 28,347 | $67.78 | $1,921,359.66 | |
| 6/1/2016 | Michael D Stanley | Insider | Sell | 14,778 | $67.78 | $1,001,652.84 | |
| 5/16/2016 | Dominic J Andreano | SVP | Sell | 3,000 | $68.53 | $205,590.00 | |
| 5/2/2016 | Vivian Lopez-Blanco | CFO | Sell | 9,350 | $71.22 | $665,907.00 | |
| 3/11/2016 | Md Pascal J Goldschmidt | Director | Sell | 3,100 | $65.00 | $201,500.00 | |
| 2/29/2016 | Paul G Gabos | Director | Sell | 10,668 | $67.15 | $716,356.20 | |
| 12/11/2015 | Md Pascal J. Goldschmidt | Director | Sell | 5,250 | $70.99 | $372,697.50 | |
| 9/8/2015 | Cesar L. Alvarez | Director | Sell | 10,668 | $81.00 | $864,108.00 | |
| 8/27/2015 | Roger Md Medel | CEO | Sell | 100,000 | $80.27 | $8,027,000.00 | |
| 6/8/2015 | Karl B Wagner | Insider | Sell | 37,820 | $70.28 | $2,657,989.60 | |
| 6/3/2015 | Joseph M Calabro | COO | Sell | 108,071 | $70.51 | $7,620,086.21 | |
| 3/9/2015 | Md Pascal J Goldschmidt | Director | Sell | 8,500 | $71.25 | $605,625.00 | |
| 2/26/2015 | Roger Md Medel | CEO | Sell | 100,000 | $71.61 | $7,161,000.00 | |
| 2/20/2015 | Md Carlo A Waldemar | Director | Sell | 10,668 | $71.50 | $762,762.00 | |
| 2/6/2015 | Dominic J Andreano | SVP | Sell | 3,200 | $70.75 | $226,400.00 | |
| 2/6/2015 | Vivian Lopez-Blanco | CFO | Sell | 8,250 | $69.95 | $577,087.50 | |
| 2/2/2015 | Paul G Gabos | Director | Sell | 17,584 | $68.07 | $1,196,942.88 | |
| 1/30/2015 | William C Hawk | COO | Sell | 3,598 | $68.50 | $246,463.00 | |
| 11/14/2014 | Roger Md Medel | CEO | Sell | 51,290 | $62.59 | $3,210,241.10 | |
| 11/13/2014 | Roger Md Medel | CEO | Sell | 63,440 | $62.55 | $3,968,172.00 | |
| 11/7/2014 | Roger Md Medel | CEO | Sell | 128,833 | $62.60 | $8,064,945.80 | |
| 11/5/2014 | Roger Md Medel | CEO | Sell | 169,845 | $62.60 | $10,632,297.00 | |
| 11/4/2014 | Roger Md Medel | CEO | Sell | 15,052 | $62.52 | $941,051.04 | |
| 11/3/2014 | Roger Md Medel | CEO | Sell | 10,881 | $62.52 | $680,280.12 | |
| 10/31/2014 | Roger Md Medel | CEO | Sell | 61,592 | $62.58 | $3,854,427.36 | |
| 10/30/2014 | Karl B Wagner | Insider | Sell | 40,000 | $62.50 | $2,500,000.00 | |
| 10/30/2014 | Vivian Lopez-Blanco | CFO | Sell | 8,800 | $60.00 | $528,000.00 | |
| 7/30/2014 | Karl B Wagner | Insider | Sell | 80,000 | $60.00 | $4,800,000.00 | |
| 6/10/2014 | Dominic J Andreano | SVP | Sell | 2,252 | $58.48 | $131,696.96 | |
| 6/6/2014 | Karl B Wagner | Insider | Sell | 44,596 | $58.53 | $2,610,203.88 | |
| 6/5/2014 | William C Hawk | COO | Sell | 6,911 | $57.66 | $398,488.26 | |
| 6/2/2014 | David A Clark | COO | Sell | 16,230 | $57.00 | $925,110.00 | |
| 6/2/2014 | Michael D Stanley | Insider | Sell | 18,006 | $57.00 | $1,026,342.00 | |
| 5/9/2014 | Karl Wagner | Insider | Sell | 79,524 | $57.09 | $4,540,025.16 | |
| 5/9/2014 | Md Pascal Goldschmidt | Director | Sell | 30,000 | $57.11 | $1,713,300.00 | |
| 5/8/2014 | Joseph Calabro | COO | Sell | 137,500 | $57.06 | $7,845,750.00 | |
| 2/20/2014 | Dominic Andreano | SVP | Sell | 3,000 | $61.00 | $183,000.00 | |
| 2/10/2014 | Joseph Calabro | COO | Sell | 150,000 | $55.55 | $8,332,500.00 | |
| 2/10/2014 | Md Carlo Waldemar | Director | Sell | 10,668 | $55.40 | $591,007.20 | |
| 11/7/2013 | Enrique Sosa | Director | Sell | 5,334 | $107.00 | $570,738.00 | |
| 11/7/2013 | Karl Wagner | Insider | Sell | 1,800 | $107.60 | $193,680.00 | |
| 9/11/2013 | William C Hawk | COO | Sell | 3,162 | $100.62 | $318,160.44 | |
| 9/10/2013 | Dominic J Andreano | SVP | Sell | 3,718 | $99.63 | $370,424.34 | |
| 8/7/2013 | Karl Wagner | Insider | Sell | 25,000 | $98.01 | $2,450,250.00 | |
| 8/2/2013 | Joseph M Calabro | COO | Sell | 36,154 | $98.57 | $3,563,699.78 | |
| 6/3/2013 | David A Clark | COO | Sell | 8,645 | $91.01 | $786,781.45 | |
| 6/3/2013 | Michael D Stanley | Insider | Sell | 8,906 | $91.01 | $810,535.06 | |
(Data available from 1/1/2013 forward)
Headline Trends for Mednax (NYSE:MD)
Latest Headlines for Mednax (NYSE:MD)
| Source: |
|
| Date | Headline |
|---|
 | Mednax (MD) vs. China Cord Blood Corporation (CO) Financial Comparison
www.americanbankingnews.com - September 23 at 2:33 PM |
| Mednax (MD) vs. Laboratory Corporation of America Holdings (LH) Critical Contrast
www.americanbankingnews.com - September 21 at 6:26 AM |
 | Mednax Stock Down 35% Year to Date: Will It Fall Further?
finance.yahoo.com - September 20 at 6:11 AM |
| Brokers Offer Predictions for Mednax, Inc's Q3 2017 Earnings (MD)
www.americanbankingnews.com - September 19 at 7:30 AM |
| Mednax, Inc (MD) Upgraded to Overweight at KeyCorp
www.americanbankingnews.com - September 17 at 9:34 PM |
 | Stocks That Fell to Three-Year Lows in the Week of Sept. 15
www.nasdaq.com - September 17 at 7:40 PM |
| Mednax, Inc (MD) Insider John C. Pepia Sells 3,000 Shares
www.americanbankingnews.com - September 13 at 8:50 PM |
 | MEDNAX (MD) Presents At Baird's 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - September 8 at 3:28 AM |
| Mednax, Inc (MD) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 5 at 2:40 PM |
| Mednax's (MD) Hold Rating Reaffirmed at Robert W. Baird
www.americanbankingnews.com - September 3 at 1:26 PM |
| Mednax Becomes Oversold (MD)
www.nasdaq.com - August 31 at 7:10 AM |
| MEDNAX to Present at the Baird 2017 Global Healthcare Conference
finance.yahoo.com - August 30 at 6:26 AM |
| Zacks: Analysts Expect Mednax, Inc (MD) Will Announce Earnings of $0.87 Per Share
www.americanbankingnews.com - August 26 at 8:18 PM |
 | Pro-Trader Daily: Featured Company News - MEDNAX Acquires Leading South Florida Radiology Practice
www.finanznachrichten.de - August 25 at 8:18 AM |
| Featured Company News - MEDNAX Acquires Leading South Florida Radiology Practice
finance.yahoo.com - August 25 at 8:18 AM |
| MEDNAX Announces Acquisition of Leading South Florida Radiology Practice
finance.yahoo.com - August 24 at 9:06 AM |
| Mednax buys Miami practice with over 70 physicians
finance.yahoo.com - August 24 at 9:06 AM |
| See what the IHS Markit Score report has to say about MEDNAX Inc.
finance.yahoo.com - August 16 at 6:05 AM |
| ETFs with exposure to MEDNAX, Inc. : August 14, 2017
finance.yahoo.com - August 15 at 1:24 AM |
| Mednax, Inc (NYSE:MD) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 11 at 3:08 PM |
| Head to Head Comparison: Universal Health Services (UHS) & Mednax (NYSE:MD)
www.americanbankingnews.com - August 5 at 7:14 AM |
| BidaskClub Downgrades Mednax, Inc (NYSE:MD) to Strong Sell
www.americanbankingnews.com - August 4 at 10:36 PM |
| Mednax, Inc (MD) Receives Neutral Rating from Mizuho
www.americanbankingnews.com - August 1 at 11:08 AM |
| MEDNAX, Inc. :MD-US: Earnings Analysis: Q2, 2017 By the Numbers : July 31, 2017
finance.yahoo.com - July 31 at 8:07 PM |
| MEDNAX (MD) Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - July 29 at 7:46 PM |
| Mednax, Inc (NYSE:MD) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - July 29 at 2:53 PM |
| MEDNAX Reports Second Quarter GAAP EPS of $0.69
finance.yahoo.com - July 29 at 4:28 AM |
| Edited Transcript of MD earnings conference call or presentation 28-Jul-17 2:00pm GMT
finance.yahoo.com - July 29 at 4:28 AM |
| Mednax misses Street 2Q forecasts
finance.yahoo.com - July 29 at 4:28 AM |
| Mednax, Inc (NYSE:MD) Issues Quarterly Earnings Results
www.americanbankingnews.com - July 28 at 6:38 PM |
 | Why Mednax Tumbled 12% Today Despite Higher Sales
www.fool.com - July 28 at 12:50 PM |
| Mednax, Inc (MD) Releases Q3 Earnings Guidance
www.americanbankingnews.com - July 28 at 10:23 AM |
| Critical Contrast: Mednax (MD) vs. TeamHealth Holdings (TMH)
www.americanbankingnews.com - July 25 at 11:02 AM |
| ETFs with exposure to MEDNAX, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 6:28 PM |
| $851.11 Million in Sales Expected for Mednax, Inc (NYSE:MD) This Quarter
www.americanbankingnews.com - July 21 at 7:35 PM |
| MEDNAX, Inc. breached its 50 day moving average in a Bearish Manner : MD-US : July 20, 2017
finance.yahoo.com - July 21 at 2:10 AM |
| MEDNAX 2017 Second Quarter Conference Call/Webcast Scheduled for Friday, July 28, 2017
finance.yahoo.com - July 18 at 11:14 PM |
| Mednax, Inc (MD) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - July 17 at 2:50 PM |
| ETFs with exposure to MEDNAX, Inc. : July 14, 2017
finance.yahoo.com - July 15 at 6:21 AM |
| MEDNAX Radiology and vRad to Exhibit at AHRA 2017 Annual Meeting
finance.yahoo.com - July 11 at 1:27 AM |
| Mednax, Inc (NYSE:MD) Given "Hold" Rating at Jefferies Group LLC
www.americanbankingnews.com - July 9 at 7:22 AM |
| Q3 2017 Earnings Forecast for Mednax, Inc (NYSE:MD) Issued By Jefferies Group
www.americanbankingnews.com - July 7 at 10:53 AM |
| ETFs with exposure to MEDNAX, Inc. : July 4, 2017
finance.yahoo.com - July 4 at 6:43 PM |
| Analysts Anticipate Mednax, Inc (MD) Will Post Quarterly Sales of $850.54 Million
www.americanbankingnews.com - June 25 at 1:02 PM |
| Mednax, Inc (MD) Upgraded to Overweight at Stephens
www.americanbankingnews.com - June 25 at 7:11 AM |
| Mednax, Inc (MD) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - June 23 at 7:38 PM |
| Zacks: Analysts Expect Mednax, Inc (MD) to Announce $0.81 Earnings Per Share
www.americanbankingnews.com - June 23 at 11:32 AM |
| Mednax, Inc. Reaches Analyst Target Price
www.nasdaq.com - June 22 at 8:44 AM |
| MEDNAX, Inc. breached its 50 day moving average in a Bullish Manner : MD-US : June 22, 2017
finance.yahoo.com - June 22 at 8:44 AM |
| MEDNAX Announces Acquisition of Maternal-Fetal Medicine Practice in Tennessee
finance.yahoo.com - June 20 at 7:28 PM |
Mednax (MD) Chart for Monday, September, 25, 2017
